Live Breaking News & Updates on Associated Vasculitis|Page 8

Stay updated with breaking news from Associated vasculitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc. and Encourages Investors to Contact the Firm


Message :
Required fields
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased ChemoCentryx, Inc. (NASDAQ: CCXI) securities between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). Investors have until July 6, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Class Period commences on November 26, 2019. After the market closed on November 25, 2019, ChemoCentryx issued a press release announcing “Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis.” Throughout the Class Period, the defendants lauded the results of the ADVOCATE Phase III trial, as well as the safety profile of avac ....

United States , Brandon Walker , Bragar Eagel Squire , Melissa Fortunato , Marion Passmore , United States District Court , Drug Administration , Chemocentryx Inc , Bragar Eagel , Northern District , Class Period , Topline Data , Pivotal Phase , Demonstrating Avacopan , Superiority Over Standard , Associated Vasculitis , United States Food , Briefing Document , New Drug Application , ஒன்றுபட்டது மாநிலங்களில் , பிராண்டன் வாக்கர் , மெலிசா அதிர்ஷ்டம் , மரியன் பாஸ்மோர் , ஒன்றுபட்டது மாநிலங்களில் மாவட்டம் நீதிமன்றம் , வடக்கு மாவட்டம் , வர்க்கம் காலம் ,